

Short Note

5,6-Dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione

Timofey N. Chmovzh ^{1,2} , Karim S. Gaisin ^{1,3} and Oleg A. Rakitin ^{1,*} 

¹ N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Prospekt, Moscow 119991, Russia; tim1661@yandex.ru (T.N.C.); tropical789castle@gmail.com (K.S.G.)

² Nanotechnology Education and Research Center, South Ural State University, 76 Lenina Avenue, Chelyabinsk 454080, Russia

³ Department of Chemistry, Moscow State University, Moscow 119899, Russia

* Correspondence: orakitin@ioc.ac.ru; Tel.: +74-99-135-5327

Abstract: 1,2,5-Chalcogenadiazoles fused with electron-withdrawing heterocycles have been actively investigated for the preparation of organic photovoltaic materials. [1,2,5]Oxadiazolo[3,4-*d*]pyridazines are much less studied than other chalcogenadiazolopyridazines due to their low availability. In this communication, we report our study showing that 5,6-dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione, a key precursor for the synthesis of 4,7-dihalo-[1,2,5]oxadiazolo[3,4-*d*]pyridazines, is formed via the cyclization of 1,2,5-oxadiazole-3,4-dicarbohydrazide in hydrochloric acid. The structure of the newly synthesized compound was established by means of elemental analysis; high-resolution mass spectrometry; ¹H and ¹³C NMR; IR spectroscopy, and mass spectrometry.

Keywords: [1,2,5]oxadiazolo[3,4-*d*]pyridazines; ring closure; 5,6-dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione

1. Introduction

The oxadiazolopyridazine heterocyclic system has been of interest to organic chemists for the past 50 years. The main attention is paid to various *N*-oxide derivatives of this heterocycle, including 1,2,5-oxadiazole *N*-oxides and pyridazine-di-*N*-oxides, which have been actively investigated as nitric oxide donors [1,2] and as high-energy compounds [1,3,4]. [1,2,5]Oxadiazolo[3,4-*d*]pyridazines are much less studied since the methods for their synthesis are limited by the deoxygenation of the corresponding 1,2,5-oxadiazole *N*-oxides. Meanwhile, these compounds have been studied for photovoltaic applications [5,6]. 4,7-Dihalo-substituted 2,1,3-benzoxadiazoles are important precursors for the synthesis of organic solar cell (OSC) and organic light-emitting diode (OLED) components [7]. The sulfur-containing analog of the oxadiazolopyridazine, 4,7-dibromo-[1,2,5]thiadiazolo pyridazine, has previously been shown to be a key precursor for a number of photovoltaic materials [8–10]. 4,7-Dihalo-[1,2,5]oxadiazolo[3,4-*d*]pyridazines can also act as useful compounds for the preparation of such materials. The key intermediate for the synthesis of these heterocycles is 5,6-dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione **1**, which can be obtained from 1,2,5-oxadiazole-3,4-dicarbohydrazide **2** [11] via a procedure similar to the synthesis of 5,6-dihydro-[1,2,5]thiadiazolo[3,4-*d*]pyridazine-4,7-dione [12]. Herein, we report a study on the cyclization reaction of 1,2,5-oxadiazole-3,4-dicarbohydrazide **2** to 5,6-dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione **1**.

2. Results and Discussion

We studied the reaction of closing the pyridazine ring in 1,2,5-oxadiazole-3,4-dicarboxylic acid dicarbohydrazide **2** under the action of hydrochloric acid in order to obtain 5,6-dihydro-[1,2,5]oxadiazolo [3,4-*d*]pyridazine-4,7-dione **1**. Previously, we showed [12] that the closure of the pyridazine ring into dicarbohydrazide 1,2,5-thiadiazole-3,4-dicarboxylic acid proceeded successfully by refluxing in a 2N HCl solution for 6 h. However, attempts



Citation: Chmovzh, T.N.; Gaisin, K.S.; Rakitin, O.A. 5,6-Dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione. *Molbank* **2023**, *2023*, M1649. <https://doi.org/10.3390/M1649>

Academic Editor: Fawaz Aldabbagh

Received: 24 April 2023

Accepted: 16 May 2023

Published: 18 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

to apply this method to dicarbohydrazide 1,2,5-oxadiazole-3,4-dicarboxylic acid **2** were unsuccessful. Instead of the precipitation of compound **1**, a clear brown solution was formed. Using thin-layer chromatography, it was shown that bis-hydrazide **2** completely reacted with 2N hydrochloric acid for 3 h at 75 °C. However, the yield of the target dihydropyridazindione **1** isolated via extraction with ethyl acetate was only 15% (Table 1, entry 1). It has been established that the reason for the low yield of dione **1** is its decomposition into a mixture of unidentifiable compounds when heated in 2N hydrochloric acid; thus, complete decomposition of dione **1** was observed upon heating for 6 h. The best yield of [1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione **1** (41%) was obtained by heating the reaction mixture for 1 h at 75 °C (Table 1, entry 3). A decrease in the temperature of the reaction mixture from 75 °C to 60 °C, as well as an increase in the temperature to 90 °C, did not lead to an increase in the yield of the target product **1** (Table 1, entries 4 and 5).

Table 1. Reaction of 1,2,5-oxadiazole-3,4-dicarbohydrazide **2** with hydrochloric acid.

Reaction scheme: 1,2,5-oxadiazole-3,4-dicarbohydrazide (**2**) reacts with HCl and H₂O under heating to form 5,6-dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione (**1**).

Entry	Temperature, °C	Time, h	Yield, of 1 , %
1	75	3	15
2	75	2	25
3	75	1	41
4	60	1	39
5	90	1	28

The structure of 5,6-dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione **1** was confirmed by means of elemental analysis; high-resolution mass spectrometry; ¹H and ¹³C NMR; IR spectroscopy, and mass spectrometry.

In conclusion, 5,6-dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione **1** was synthesized via the ring closure reaction of 1,2,5-oxadiazole-3,4-dicarbohydrazide **2** with hydrochloric acid. The compound obtained may serve as a precursor for the preparation of 4,7-dihalo-[1,2,5]oxadiazolo[3,4-*d*]pyridazines.

3. Materials and Methods

1,2,5-Oxadiazole-3,4-dicarbohydrazide **2** was prepared according to the published method [11]. The solvents and reagents were purchased from commercial sources and used as received. Elemental analysis was performed using a 2400 Elemental Analyzer (Perkin Elmer Inc., Waltham, MA, USA). The ¹H and ¹³C NMR spectra were obtained with a Bruker AM-300 machine (Bruker AXS Handheld Inc., Kennewick, WA, USA) (at frequencies of 300 and 75 MHz) in an acetone-*d*₆ solution, with TMS as the standard. The MS spectrum (EI, 70 eV) was obtained with a Finnigan MAT INCOS 50 instrument (Hazlet, NJ, USA). The high-resolution MS spectrum was measured using a Bruker micrOTOF II instrument (Bruker Daltonik GmbH, Bremen, Germany) with electrospray ionization (ESI). The IR spectrum was measured with a Bruker "Alpha-T" instrument in KBr pellet.

5,6-Dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione **1** (CAS 898057-22-2) was commercially available from Aurora Fine Chemicals LLC (San Diego, CA, USA).

Synthesis of 5,6-dihydro-[1,2,5]oxadiazolo[3,4-*d*]pyridazine-4,7-dione **1** (Supplementary Materials).

1,2,5-Oxadiazole-3,4-dicarbohydrazide **2** (100 mg, 0.53 mmol), H₂O (20 mL), and conc. HCl (0.6 mL) were added to a 50 mL three-necked flask. The mixture was stirred for 1 h at

75 °C and then cooled to room temperature; water (10 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO₄, and the solvent was evaporated under reduced pressure. The residue was separated using silica gel column chromatography (eluent: CH₂Cl₂/EtOH = 10:1). The yield was 33 mg (41%), as a yellow solid, and R_f = 0.1 (CH₂Cl₂). Mp = 240–243 °C. IR spectrum, ν , cm⁻¹: 3109, 3038, 2931, 2850, 1725, 1679, 1324, 1120, 1023, 828, 722, 641, and 511. ¹H NMR (ppm): δ 10.1 (2H, s, NH). ¹³C NMR (ppm): δ 146.3 and 148.9. HRMS (ESI-TOF), m/z : calcd. for C₄H₃N₄O₃ [M + H]⁺ 155.0200 and found 155.0203. MS (EI, 70eV), m/z (*I*, %): 154 ([M]⁺, 40), 70 (20), and 30 (100). Anal. calcd. for C₄H₃N₄O₃ (288.2952): C, 30.96; H, 1.95; and N, 36.13%. Found: C, 31.25; H, 2.04 %; and N, 36.47%.

Supplementary Materials: The following are available online: copies of the ¹H, ¹³C NMR, IR, and LR and HR mass-spectra for the compound **1**.

Author Contributions: Conceptualization, O.A.R.; methodology, T.N.C.; software, T.N.C.; validation, O.A.R.; formal analysis and investigation, T.N.C. and K.S.G.; resources, T.N.C.; data curation, T.N.C.; writing—original draft preparation, O.A.R.; writing—review and editing, O.A.R.; visualization, O.A.R.; supervision, O.A.R.; project administration, O.A.R.; funding acquisition, O.A.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of compound **1** are available from the authors.

References

- Ogurtsov, V.A.; Dorovatovskii, P.V.; Zubavichus, Y.V.; Khrustalev, V.N.; Fakhrutdinov, A.N.; Zlotin, S.G.; Rakitin, O.A. [1,2,5]Oxadiazolo[3,4-d]pyridazine 1,5,6-trioxides: Efficient synthesis via the reaction of 3,4-bis(hydroxyimino)methyl-1,2,5-oxadiazole 2-oxides with a mixture of concentrated nitric and trifluoroacetic acids and structural characterization. *Tetrahedron Lett.* **2018**, *59*, 3143–3146. [[CrossRef](#)]
- Kots, A.Y.; Khropov, Y.V.; Grafov, M.A.; Kulikov, A.S.; Ovchinnikov, I.V.; Belushkina, N.N.; Busygina, O.G.; Gavrilova, S.A.; Makhova, N.N.; Medvedeva, N.A.; et al. 1,2,5-Oxadiazolo[3,4-d]pyridazine-5,6-dioxide derivatives as activators of soluble form of guanylate-cyclase and agents active in the treatment of central nervous system diseases. Russian Patent RU2165256, 20 April 2001.
- Tang, Y.; He, C.; Imler, G.H.; Parrish, D.A.; Shreeve, J.M. Energetic 1,2,5-Oxadiazolo-Pyridazine and its N-Oxide. *Chem. A Eur. J.* **2017**, *23*, 15022–15025. [[CrossRef](#)]
- Zheng, Y.; Qi, X.; Chen, S.; Song, S.; Zhang, Y.; Wang, K.; Zhang, Q. Self-Assembly of Nitrogen-Rich Heterocyclic Compounds with Oxidants for the Development of High-Energy Materials. *ACS Appl. Mater. Interfaces* **2021**, *13*, 28390–28397. [[CrossRef](#)]
- Gendron, D.; Morin, P.-O.; Najari, A.; Leclerc, M. Synthesis of New Pyridazine-Based Monomers and Related Polymers for Photovoltaic Applications. *Macromol. Rapid Commun.* **2010**, *31*, 1090–1094. [[CrossRef](#)]
- Chmovzh, T.N.; Gaisin, K.S.; Rakitin, O.A. 4,7-Bis(1,2,3,4,4a,9a-Hexahydro-9H-carbazol-9-yl)-[1,2,5]oxadiazolo[3,4-d]pyridazine. *Molbank* **2021**, *2021*, M1295. [[CrossRef](#)]
- Knyazeva, E.A.; Rakitin, O.A. 4,7-Dibromo-substituted 2,1,3-benzothia(selena,oxa)diazoles and [1,2,5]thia(selena)diazolo pyridines as building blocks in solar cells components. *Chem. Heterocycl. Comp.* **2017**, *53*, 855–857. [[CrossRef](#)]
- Chmovzh, T.N.; Knyazeva, E.A.; Mikhailchenko, L.V.; Golovanov, I.S.; Amelichev, S.A.; Rakitin, O.A. Synthesis of 4,7-dibromo derivative of ultrahigh electron-deficient [1,2,5]thiadiazolo[3,4-d]pyridazine heterocycle and its cross-coupling reactions. *Eur. J. Org. Chem.* **2018**, *41*, 5668–5677. [[CrossRef](#)]
- Chmovzh, T.N.; Knyazeva, E.A.; Tanaka, E.; Popov, V.V.; Mikhailchenko, L.V.; Robertson, N.; Rakitin, O.A. [1,2,5]Thiadiazolo pyridazine as an internal acceptor in the D-A- π -A organic sensitizers for dye-sensitized solar cells. *Molecules* **2019**, *24*, 1588. [[CrossRef](#)] [[PubMed](#)]
- Korshunov, V.M.; Chmovzh, T.N.; Chkhetiani, G.R.; Taydakov, I.V.; Rakitin, O.A. New D–A–D luminophores of the [1,2,5]thiadiazolo[3,4-d]pyridazine series. *Mendeleev Commun.* **2022**, *32*, 371–373. [[CrossRef](#)]

11. Ereemeev, A.V.; Andrianov, V.G.; Piskunova, I.P. Reaction of functionally substituted vinyl ethers with 3,4-diaminofurazan and furazan-3,4-dicarboxylic acid dihydrazide. *Chem. Heterocycl. Compd.* **1979**, *15*, 261–264. [[CrossRef](#)]
12. Chmovzh, T.N.; Knyazeva, E.A.; Lyssenko, K.A.; Popov, V.V.; Rakitin, O.A. Safe synthesis of 4,7-dibromo[1,2,5]thiadiazolo pyridazine and its S_NAr reactions. *Molecules* **2018**, *23*, 2576. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.